Fluvestrant

Fluvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy . It is given by injection into a muscle.

Here's how Fluvestrant works:

• It acts as an antagonist of the estrogen receptor (ER), essentially blocking the effects of estrogen on breast cancer cells.
• Additionally, it works as a selective estrogen receptor degrader (SERD), causing the estrogen receptor to breakdown and be eliminated by the body.
• By decreasing the effect of estrogen and eliminating estrogen receptors, fulvestrant helps slow or stop the growth of some breast cancers.

It is important to note that Fluvestrant is only prescribed for postmenopausal women. This is because the medication works by blocking the effects of estrogen, and since menopause is the natural decrease in estrogen production, Fluvestrant would not be effective in women who are still producing estrogen.